Authors
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Another European Study Finds SB4 Tolerated by Most PatientsThe study follows others that have found that SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.
Latest:
Lupin Partners With Mylan on Etanercept BiosimilarLupin recently announced that it has entered into a partnership agreement with Mylan to commercialize its proposed etanercept (Enbrel) biosimilar.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Dr Andre Harvin Answers How Oncologists Can Work to Expand Access to BiosimilarsAndre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, explains how oncologists can work with other stakeholders to expand access to biosimilars and how patients can work with providers and biosimilar manufacturers to address financial challenges.
Latest:
Using Biosimilar Filgrastim May Lead to Shorter Hospitalization, Lower Cost in PBSC MobilizationUsing the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.
Latest:
Federal Perspective on the Biosimilar Influence on Drug CostsProviding an overview on where the healthcare reform debate is headed, Andrew Slavitt, former head of CMS, refined the discussion to highlight the potential for biosimilars to influence the rising costs of drug products.
Latest:
Selecting Between Adalimumab Biosimilars for Your PatientsProviders in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.
Latest:
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End PointsEculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
Latest:
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial LaunchIn a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Latest:
Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.
Latest:
Opinion: Purple Book Patent Listings Are Only a First StepIntellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Latest:
Biosimilar Nonmedical Switching Must Never Undermine Patient SafetyWhile managing costs is extremely important to physicians and their patients, achieving and maintaining disease control without increasing the risk of complications or toxicities must remain the primary goal in the treatment of chronic inflammatory diseases.
Latest:
Contributor: Drug Delivery Devices Help Originator Companies Retain Market ShareAmgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.
Latest:
Supportive Care in Oncology Therapy: Pegfilgrastim Biosimilars in the PipelinePegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.
Latest:
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment ModelsA simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Latest:
Quiz: Biosimilar Market Dynamics and TrendsHave you been keeping up with the latest market trends? Take this quiz to find out how well you know the global biosimilars market.
Latest:
Part D Beneficiaries May Pay More for Some Generics, Biosimilars Than Brand-Name DrugsMedicare Part D enrollees may actually pay more for some generic drugs than they would for their brand-name counterparts because of the Part D benefit, according to findings of a new study appearing in Health Affairs.
